Eris Lifesciences Limited (NSE: ERIS)
India
· Delayed Price · Currency is INR
1,374.20
+7.30 (0.53%)
Nov 22, 2024, 3:29 PM IST
Eris Lifesciences Cash Flow Statement
Financials in millions INR. Fiscal year is April - March.
Millions INR. Fiscal year is Apr - Mar.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2019 - 2015 |
---|---|---|---|---|---|---|---|
Period Ending | Sep '24 Sep 30, 2024 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 | Mar '21 Mar 31, 2021 | Mar '20 Mar 31, 2020 | 2019 - 2015 |
Net Income | 3,485 | 3,920 | 3,822 | 4,061 | 3,551 | 2,965 | Upgrade
|
Depreciation & Amortization | 2,532 | 1,798 | 1,144 | 626.21 | 423.02 | 498.55 | Upgrade
|
Other Amortization | 28.19 | 28.19 | 26.58 | 20.84 | 6.83 | 4.03 | Upgrade
|
Loss (Gain) From Sale of Assets | 21.41 | 21.41 | 20.18 | 42.54 | 0.06 | 0.87 | Upgrade
|
Loss (Gain) From Sale of Investments | -70.76 | -93.76 | -69.33 | -167.61 | -49.77 | -86.22 | Upgrade
|
Stock-Based Compensation | 32.7 | 7.5 | 31.21 | 13.55 | 11.2 | 16.61 | Upgrade
|
Provision & Write-off of Bad Debts | 2.1 | - | 0.67 | 0.02 | 65.1 | 18.78 | Upgrade
|
Other Operating Activities | 1,412 | 166.41 | -302.45 | -515.03 | -307.45 | -179.43 | Upgrade
|
Change in Accounts Receivable | -387.63 | -570.93 | -1,171 | -204.8 | 158.96 | -747.86 | Upgrade
|
Change in Inventory | -263.9 | -169.4 | 47.44 | -234.45 | -249.91 | 131.78 | Upgrade
|
Change in Accounts Payable | 511.48 | 909.78 | -104.97 | 151.59 | 25.66 | 159.34 | Upgrade
|
Change in Other Net Operating Assets | -234.04 | -1,157 | -526.45 | -11.35 | 118.56 | -69.76 | Upgrade
|
Operating Cash Flow | 7,068 | 4,860 | 2,917 | 3,783 | 3,754 | 2,712 | Upgrade
|
Operating Cash Flow Growth | 58.98% | 66.59% | -22.87% | 0.77% | 38.42% | 21.60% | Upgrade
|
Capital Expenditures | -1,137 | -1,292 | -8,414 | -1,210 | -257.63 | -1,513 | Upgrade
|
Sale of Property, Plant & Equipment | -3.7 | - | 1.37 | 7.58 | 0.38 | 54.67 | Upgrade
|
Cash Acquisitions | -17,358 | -5,668 | -6,555 | - | - | -213.73 | Upgrade
|
Investment in Securities | -47.04 | 484.06 | 4,904 | -1,881 | -2,946 | 2,880 | Upgrade
|
Other Investing Activities | 473.35 | -12,053 | 35.61 | 49.32 | -0.4 | 12.95 | Upgrade
|
Investing Cash Flow | -18,816 | -18,545 | -9,821 | -3,196 | -3,234 | 1,232 | Upgrade
|
Long-Term Debt Issued | - | 16,231 | 11,678 | 450.01 | 0.1 | - | Upgrade
|
Short-Term Debt Repaid | - | - | - | - | - | -1,755 | Upgrade
|
Long-Term Debt Repaid | - | -1,603 | -3,587 | -115.01 | -59.45 | -86.02 | Upgrade
|
Total Debt Repaid | -11,341 | -1,603 | -3,587 | -115.01 | -59.45 | -1,841 | Upgrade
|
Net Debt Issued (Repaid) | 14,662 | 14,628 | 8,091 | 335 | -59.35 | -1,841 | Upgrade
|
Issuance of Common Stock | 69.43 | 45.43 | 22.78 | 71.96 | - | - | Upgrade
|
Repurchase of Common Stock | - | - | - | - | - | -1,000 | Upgrade
|
Common Dividends Paid | - | - | -999.11 | -816.23 | -746.79 | -389.69 | Upgrade
|
Other Financing Activities | -3,480 | -875.77 | -234.3 | -37.72 | -17.81 | -115.12 | Upgrade
|
Financing Cash Flow | 11,251 | 13,798 | 6,880 | -446.99 | -823.95 | -3,346 | Upgrade
|
Miscellaneous Cash Flow Adjustments | 269.61 | 269.61 | 74.9 | - | - | - | Upgrade
|
Net Cash Flow | -226.97 | 382.23 | 51.52 | 139.55 | -303.92 | 598.07 | Upgrade
|
Free Cash Flow | 5,931 | 3,568 | -5,497 | 2,572 | 3,496 | 1,199 | Upgrade
|
Free Cash Flow Growth | - | - | - | -26.42% | 191.61% | -35.20% | Upgrade
|
Free Cash Flow Margin | 23.87% | 17.92% | -33.08% | 19.40% | 29.31% | 11.33% | Upgrade
|
Free Cash Flow Per Share | 43.54 | 26.21 | -40.37 | 18.93 | 25.73 | 8.73 | Upgrade
|
Cash Interest Paid | 1,105 | 772.97 | 234.3 | 38.5 | 17.81 | 18.25 | Upgrade
|
Cash Income Tax Paid | 1,091 | 1,008 | 772.08 | 832.85 | 685.35 | 597.81 | Upgrade
|
Levered Free Cash Flow | 2,992 | 2,357 | -6,892 | 1,623 | 2,560 | 507.32 | Upgrade
|
Unlevered Free Cash Flow | 4,061 | 2,887 | -6,729 | 1,649 | 2,571 | 520.84 | Upgrade
|
Change in Net Working Capital | 1,074 | 770.28 | 2,152 | 454.82 | 34.78 | 497.11 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.